Gene Silencing Global Market Report 2025

The gene silencing market size has grown rapidly in recent years. It will grow from $5.97 billion in 2024 to $6.75 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth during the historic period can be attributed to the growing research in genetic therapies, early breakthroughs in RNA interference, the increasing prevalence of genetic disorders, rising investment in biotechnology, and the expanding biopharmaceutical manufacturing capabilities.

The gene silencing market size is expected to see rapid growth in the next few years. It will grow to $10.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the expanding applications in rare diseases, technological advancements in delivery systems, increasing demand for personalized medicine, supportive government initiatives, and growing partnerships between pharmaceutical and biotechnology companies. Major trends expected during this period include the development of targeted gene therapies, the rise of CRISPR-based silencing approaches, a greater focus on rare and orphan diseases, the emergence of nanoparticle delivery technologies, and the expansion of gene silencing applications into agriculture.

The growing prevalence of genetic disorders is expected to significantly drive the expansion of the gene silencing market in the coming years. Genetic disorders, which are health conditions caused by DNA abnormalities, are being increasingly detected due to advancements in diagnostic technologies, improved awareness, and wider access to genetic testing. One of the main contributors to the rising incidence of genetic disorders is the increasing age of parents, which raises the likelihood of genetic mutations being passed to their children. Gene silencing presents a promising solution for addressing genetic disorders by selectively inhibiting the expression of harmful or disease-causing genes. For example, according to Down Syndrome UK, a charity based in the UK, Down syndrome affects around 40,000 people in the UK, with approximately 1 in every 800 babies being born with the condition. This growing prevalence of genetic disorders is fueling the gene silencing market.

Leading companies in the gene silencing market are focusing on the development of innovative technologies, such as small interfering RNA (siRNA), to improve the precision and efficacy of gene therapy. Small interfering RNA (siRNA) is an RNA molecule that plays a key role in the RNA interference (RNAi) pathway by binding to specific messenger RNA (mRNA) and promoting its degradation, thereby preventing the production of disease-causing proteins. For instance, in October 2024, Judo Bio Inc., a biotechnology company based in the US, launched a next-generation siRNA drug designed to silence genes. The drug incorporates proprietary delivery systems, such as lipid nanoparticles or conjugated ligands, which ensure efficient uptake by specific cells or tissues, along with AI-driven platforms that accelerate the identification of potential gene targets.

In September 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Decibel Therapeutics for an undisclosed amount. This acquisition aims to strengthen Regeneron’s genetic medicine and gene therapy capabilities, with a particular focus on developing treatments for sensory disorders, such as genetic hearing loss. Decibel Therapeutics, a US-based company, specializes in gene therapies for hearing loss, including its lead program, DB-OTO, which utilizes a gene silencing approach.

Major players in the gene silencing market are Roche Holding AG, Merck & Co. Inc., AstraZeneca plc, Novartis International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Alnylam Pharmaceuticals Inc., GenScript Biotech Corporation, Oxford BioMedica plc, Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., New England Biolabs Inc., Quark Pharmaceuticals Inc., Sirion Biotech GmbH, Benitec Biopharma Limited, GeneCopoeia Inc., Revvity Inc.

North America was the largest region in the gene silencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene silencing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gene silencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gene silencing is a biological process in which the expression of a specific gene is reduced or completely turned off. This process plays a crucial role in regulating gene activity, controlling development, and defending against viral infections. Gene silencing is essential in both research and medicine, particularly for targeting disease-related genes.

The main types of gene silencing include transcriptional, post-transcriptional, and meiotic. Transcriptional silencing refers to the regulation of gene expression at the transcription stage, where RNA is synthesized from a DNA template. Key gene silencing techniques include RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR/Cas9-based gene silencing, among others. These methods are applied across various fields such as neurology, oncology, infectious diseases, metabolic diseases, and therapeutic manufacturing. The primary end-users of gene silencing technologies include pharmaceutical and biotechnology companies, research institutes and academic centers, hospitals, clinics, and other related organizations.

The gene silencing market research report is one of a series of new reports that provides gene silencing market statistics, including the gene silencing industry global market size, regional shares, competitors with the gene silencing market share, detailed gene silencing market segments, market trends, and opportunities, and any further data you may need to thrive in the gene silencing industry. These gene silencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gene silencing market consists of revenues earned by entities by providing services such as services such as gene knockdown assays, RNAi screening services, and epigenetic gene silencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholestatic pruritus market also includes sales of small interfering RNA, miRNA mimics and inhibitors, reporter assay kits, and therapeutic RNAi-based drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.